Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see ...

Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by weight loss, loss of muscle mass, fatigue, and lack of appetite, and is ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

The Pfizer-sponsored study enrolled 187 participants across the world — including 10 from Oregon Health & Science University, ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Ponsegromab, a monoclonal antibody treatment from Pfizer, showed promising results in a clinical study aimed at treating the wasting condition cachexia in cancer patients. Patients treated with ...

A phase 2 trial of ponsegromab has shown promising results in treating cancer cachexia, a condition that leads to severe weight and muscle loss, according to a study published Sept. 14 in the New ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...